Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-15, 2024, in Boston, MA.
Key details of Biora's participation include:
- Company presentation on Tuesday, August 13, 2024, at 2:30 PM Eastern time
- One-on-one investor meetings
- Live webcast available at https://wsw.com/webcast/canaccord98/bior/2458676
- Replay of the presentation will be accessible on Biora's website after the conference
This participation provides an opportunity for Biora to showcase its innovations in therapeutic delivery to potential investors and industry professionals.
Biora Therapeutics (Nasdaq: BIOR), una compagnia biotech focalizzata sulla riprogettazione della somministrazione terapeutica, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. L'evento si terrà dal 13 al 15 agosto 2024 a Boston, MA.
I dettagli principali della partecipazione di Biora includono:
- Presentazione dell'azienda il martedì 13 agosto 2024, alle 14:30 ora orientale
- Incontri individuali con gli investitori
- Webcast in diretta disponibile all'indirizzo https://wsw.com/webcast/canaccord98/bior/2458676
- Replay della presentazione sarà accessibile sul sito web di Biora dopo la conferenza
Questa partecipazione offre a Biora l'opportunità di mostrare le proprie innovazioni nella somministrazione terapeutica a potenziali investitori e professionisti del settore.
Biora Therapeutics (Nasdaq: BIOR), una empresa biotecnológica centrada en reinventar la entrega terapéutica, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El evento está programado para el 13 al 15 de agosto de 2024 en Boston, MA.
Los detalles clave de la participación de Biora incluyen:
- Presentación de la empresa el martes 13 de agosto de 2024, a las 2:30 PM hora del este
- Reuniones personales con inversores
- Webcast en vivo disponible en https://wsw.com/webcast/canaccord98/bior/2458676
- La repetición de la presentación estará accesible en el sitio web de Biora después de la conferencia
Esta participación ofrece a Biora la oportunidad de mostrar sus innovaciones en la entrega terapéutica a posibles inversores y profesionales de la industria.
Biora Therapeutics (Nasdaq: BIOR), 치료 전달 방식을 재구성하는 데 중점을 둔 생명공학 회사가 Canaccord Genuity 제44회 연례 성장 콘퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 8월 13일부터 15일까지 보스턴, MA에서 열립니다.
Biora의 참가 주요 내용은 다음과 같습니다:
- 2024년 8월 13일 화요일, 동부 표준시 기준 오후 2시 30분에 회사 발표
- 개별 투자자와의 미팅
- https://wsw.com/webcast/canaccord98/bior/2458676에서 송출되는 라이브 웹캐스트
- 콘퍼런스 이후 Biora 웹사이트에서 발표 재생 가능
이 참여는 Biora에게 치료 전달 혁신을 잠재 투자자 및 산업 전문가에게 선보일 기회를 제공합니다.
Biora Therapeutics (Nasdaq: BIOR), une entreprise de biotechnologie spécialisée dans la réinvention de l'administration thérapeutique, a annoncé sa participation à la 44ème Conférence Annuelle sur la Croissance de Canaccord Genuity. L'événement aura lieu du 13 au 15 août 2024 à Boston, MA.
Les principaux détails de la participation de Biora comprennent :
- Présentation de l'entreprise le mardi 13 août 2024, à 14h30 heure de l'Est
- Réunions individuelles avec des investisseurs
- Webdiffusion en direct disponible sur https://wsw.com/webcast/canaccord98/bior/2458676
- La rediffusion de la présentation sera accessible sur le site web de Biora après la conférence
Cette participation offre à Biora l'opportunité de présenter ses innovations en matière d'administration thérapeutique à des investisseurs potentiels et à des professionnels de l'industrie.
Biora Therapeutics (Nasdaq: BIOR), ein Biotech-Unternehmen, das sich auf die Neugestaltung der therapeutischen Abgabe konzentriert, hat seine Teilnahme an der 44. jährlichen Wachstumsveranstaltung von Canaccord Genuity bekannt gegeben. Die Veranstaltung findet vom 13. bis 15. August 2024 in Boston, MA statt.
Wichtige Einzelheiten zur Teilnahme von Biora umfassen:
- Präsentation des Unternehmens am Dienstag, den 13. August 2024, um 14:30 Uhr Eastern Time
- Einzelgespräche mit Investoren
- Live-Stream verfügbar unter https://wsw.com/webcast/canaccord98/bior/2458676
- Aufzeichnung der Präsentation wird nach der Konferenz auf Bioras Webseite erhältlich sein
Diese Teilnahme bietet Biora die Möglichkeit, seine Innovationen im Bereich therapeutische Abgabe potenziellen Investoren und Fachleuten der Branche zu präsentieren.
- None.
- None.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the Canaccord Genuity 44th Annual Growth Conference, August 13–15, 2024.
Canaccord Genuity 44th Annual Growth Conference, Boston, MA
Company presentation and 1x1 investor meetings
Date: | Tuesday, August 13, 2024 |
Time: | 2:30 PM Eastern time |
Live Webcast: | https://wsw.com/webcast/canaccord98/bior/2458676 |
A replay will also be available on Biora’s website following the conference.
About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery for better management of chronic diseases.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model projections, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com
FAQ
When is Biora Therapeutics (BIOR) presenting at the Canaccord Genuity Growth Conference?
Where can I watch the live webcast of Biora Therapeutics' (BIOR) presentation?
Will there be a replay available of Biora Therapeutics' (BIOR) conference presentation?
What type of meetings will Biora Therapeutics (BIOR) be conducting at the Canaccord Genuity conference?